Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Scand J Rheumatol ; 51(2): 102-109, 2022 Mar.
Article in English | MEDLINE | ID: mdl-34182885

ABSTRACT

OBJECTIVE: To evaluate whether serum infliximab trough levels (ITL) during the early stages of treatment are predictive of long-term clinical failure in patients with axial spondyloarthritis (axSpA). METHODS: Longitudinal observational study involving 81 patients with axSpA monitored during infliximab therapy. Serum ITL were measured before starting infliximab treatment and at weeks 2 (W2), W6 and W12 of treatment. Disease activity was assessed by Ankylosing Spondylitis Disease Activity Score (ASDAS) at baseline, W24 and W52, and every 6 months thereafter until treatment discontinuation, regardless of the reason. Non-clinically important improvement was defined by ΔASDAS<1.1. The association between serum levels during the early stages and clinical outcomes (non-clinically important improvement at W52, drug survival and drop-out due to secondary inefficacy) was investigated through logistic regression models and Kaplan Meier curves. Receiver operating characteristic (ROC) curves were employed to determine the best cut-off for serum ITL. RESULTS: Out of the 81 patients, 45 (56%) did not achieve clinical improvement at W52. These patients had lower serum ITL at W12 compared to those who improved: ITL [median (IQR)]: 4.1(0.9-8.3) µg/mL vs 7.1 (4.3-11.3) µg/mL, respectively;p = 0.007). ITL<6.7 µg/mL at W12 was significantly associated with: i) not achieving clinical improvement at W52 (OR: 2.3; 95%CI: 1.3-3.9); ii) shorter drug survival (5.0 years (95% CI 3.8-6.2) vs 7.0 years (95% CI 4.8-6.9; p = 0.04), and iii) higher drop-out rates due to secondary inefficacy (OR: 3.5; 95% CI: 1.2-10.2). CONCLUSION: Low serum ITL at W12 were associated with long-term clinical failure in patients with axSpA, due to secondary inefficacy.


Subject(s)
Axial Spondyloarthritis , Spondylarthritis , Spondylitis, Ankylosing , Humans , Infliximab/therapeutic use , ROC Curve , Severity of Illness Index , Spondylarthritis/drug therapy , Spondylitis, Ankylosing/drug therapy
2.
Clin Exp Immunol ; 198(3): 341-350, 2019 12.
Article in English | MEDLINE | ID: mdl-31397881

ABSTRACT

Acquired angioedema due to C1-inhibitor (C1INH) deficiency (AAE) is caused by secondary C1INH deficiency leading to bradykinin-mediated angioedema episodes. AAE typically presents in adulthood and is associated with B cell lymphoproliferation. Anti-C1INH autoantibodies (antiC1INHAbs) are detectable in a subset of AAE cases and considered a hallmark of the disease. When free antiC1INHAbs and malignant tumors are not detectable, diagnosis relies on the finding of low C1INH levels and/or function, lack of family history and SERPING1 mutations, age at onset and low or undetectable C1q levels, none of which is specific for AAE. We tested the diagnostic value of a novel enzyme-linked immunosorbent assay (ELISA) for the detection of circulating complexes between C1INH and antiC1INHAbs (C1INH-antiC1INHAb) in the serum of 20 European AAE patients characterized on the basis of their complement levels and function. Free antiC1INHAbs were detected in nine of 20 patients [six of immunoglobulin (Ig)G class, two of IgM class and one simultaneously presenting IgG and IgM classes], whereas C1INH-antiC1INHAb complexes were found in 18 of 20 of the AAE cases, regardless of the presence or absence of detectable free anti-C1INHAbs. Of note, nine of 20 patients showed negative free antiC1INHabs, but positive C1INH-antiC1INHAb complexes in their first measurement. In the cohort presented, IgM-class C1INH-antiC1INHAb are specifically and strongly associated with low C1q serum levels. Detection of C1INH-antiC1-INHAbs provides an added value for AAE diagnosis, especially in those cases in whom no free anti-C1INH antibodies are detected. The link between IgM-class C1INH-antiC1INHAb complexes and C1q consumption could have further implications for the development of autoimmune manifestations in AAE.


Subject(s)
Angioedema/immunology , Angioedemas, Hereditary/immunology , Autoantibodies/immunology , Complement C1 Inhibitor Protein/immunology , Multiprotein Complexes/immunology , Adult , Aged , Aged, 80 and over , Angioedema/blood , Angioedema/diagnosis , Angioedemas, Hereditary/blood , Angioedemas, Hereditary/diagnosis , Autoantibodies/blood , Autoantibodies/metabolism , Cohort Studies , Complement C1 Inhibitor Protein/genetics , Complement C1 Inhibitor Protein/metabolism , Complement C1q/immunology , Complement C1q/metabolism , Enzyme-Linked Immunosorbent Assay , Europe , Female , Humans , Male , Middle Aged , Multiprotein Complexes/blood , Multiprotein Complexes/metabolism , Mutation , Sensitivity and Specificity
3.
Rev. clín. esp. (Ed. impr.) ; 216(3): 128-134, abr. 2016. tab, graf
Article in Spanish | IBECS | ID: ibc-150040

ABSTRACT

Se presenta una guía elaborada por el grupo de Inmunoquímica de la Sociedad Española de Inmunología con el objetivo de proporcionar una herramienta práctica para el diagnóstico y seguimiento de las gammapatías monoclonales. Se revisan las características clínicas y analíticas de los diferentes tipos de gammapatía monoclonal, las guías de consenso internacionales y las técnicas utilizadas para la detección y seguimiento del componente monoclonal (AU)


We present guidelines from the Immunochemistry group of the Spanish Society for Immunology that are designed to provide a practical tool for the diagnosis and follow-up of monoclonal gammopathies. We review the clinical and analytical features of various monoclonal gammopathies, international consensus guidelines and techniques used to detect and follow-up monoclonal components (AU)


Subject(s)
Humans , Male , Female , Paraproteinemias/diagnosis , Paraproteinemias/therapy , Paraproteinemias , Immunoglobulin Light Chains , Immunoglobulin Light Chains/immunology , Plasma Cells/immunology , Plasma Cells/radiation effects , Amyloidosis/immunology , Amyloidosis , Follow-Up Studies , Societies, Medical/organization & administration , Societies, Medical/standards , Immunoglobulins/therapeutic use
4.
Rev Clin Esp (Barc) ; 216(3): 128-34, 2016 Apr.
Article in English, Spanish | MEDLINE | ID: mdl-26481802

ABSTRACT

We present guidelines from the Immunochemistry group of the Spanish Society for Immunology that are designed to provide a practical tool for the diagnosis and follow-up of monoclonal gammopathies. We review the clinical and analytical features of various monoclonal gammopathies, international consensus guidelines and techniques used to detect and follow-up monoclonal components.

5.
Clin Exp Immunol ; 184(1): 118-25, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26660535

ABSTRACT

Properdin (P) stabilizes the alternative pathway (AP) convertases, being the only known positive regulator of the complement system. In addition, P is a pattern recognition molecule able to initiate directly the AP on non-self surfaces. Although P deficiencies have long been known to be associated with Neisseria infections and P is often found deposited at sites of AP activation and tissue injury, the potential role of P in the pathogenesis of complement dysregulation-associated disorders has not been studied extensively. Serum P levels were measured in 49 patients with histological and clinical evidence of C3 glomerulopathy (C3G). Patients were divided into two groups according to the presence or absence of C3 nephritic factor (C3NeF), an autoantibody that stabilizes the AP C3 convertase. The presence of this autoantibody results in a significant reduction in circulating C3 (P < 0·001) and C5 levels (P < 0·05), but does not alter factor B, P and sC5b-9 levels. Interestingly, in our cohort, serum P levels were low in 17 of the 32 C3NeF-negative patients. This group exhibited significant reduction of C3 (P < 0·001) and C5 (P < 0·001) and increase of sC5b-9 (P < 0·001) plasma levels compared to the control group. Also, P consumption was correlated significantly with C3 (r = 0·798, P = 0·0001), C5 (r = 0·806, P < 0·0001), sC5b-9 (r = -0·683, P = 0·043) and a higher degree of proteinuria (r = -0·862, P = 0·013). These results illustrate further the heterogeneity among C3G patients and suggest that P serum levels could be a reliable clinical biomarker to identify patients with underlying surface AP C5 convertase dysregulation.


Subject(s)
Complement C3-C5 Convertases/immunology , Complement Pathway, Alternative , Glomerulonephritis/immunology , Properdin/immunology , Proteinuria/immunology , Adolescent , Adult , Biomarkers/blood , Child , Complement C3/genetics , Complement C3/immunology , Complement C3 Nephritic Factor/genetics , Complement C3 Nephritic Factor/immunology , Complement C3-C5 Convertases/genetics , Complement C5/genetics , Complement C5/immunology , Complement Factor B/genetics , Complement Factor B/immunology , Complement Inactivating Agents/blood , Complement Membrane Attack Complex/genetics , Complement Membrane Attack Complex/immunology , Female , Gene Expression Regulation , Glomerulonephritis/blood , Glomerulonephritis/genetics , Glomerulonephritis/pathology , Humans , Male , Middle Aged , Properdin/genetics , Proteinuria/blood , Proteinuria/genetics , Proteinuria/pathology , Retrospective Studies , Severity of Illness Index , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL
...